MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). Palovarotene, an […]
All posts by jay
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it plans to submit a New Drug Application (NDA) for palovarotene to the U.S. Food and […]
Recent Posts
-
Optimized Genome-Editing Method Opens The Door To More Effective Treatment Of Genetic Diseases -
Fibrodysplasia Ossificans Progressiva -
Fibrodysplasia Ossificans Progressiva Pipeline Report, 2024 Updates : In-Depth Analysis Into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects and Companies -
Successful Preimplantation Genetic Testing for Fibrodysplasia Ossificans Progressiva: a Case Report -
Actionable Disease Insights from Bedside-to-Bench Investigation in Fibrodysplasia Ossificans Progressiva